�鶹��Ƶapp

With a family history of mental illness and addiction, I was long aware the these psychiatric disorders emerge at the interface of biological, social, psychological, and psychospiritual dimensions of experience. For that reason, I became interested in psychedelic-assisted therapy research, given early data suggesting that psychedelic treatments might address clinical concerns in a holistic way.

I have been involved in psychedelic clinical research at NYU Langone since I began residency training on the research track, working with Drs. Michael Bogenschutz and Steve Ross on Phase 2 trials of psilocybin-assisted therapy
for alcohol use disorder and major depressive disorder. Since then, I’ve accumulated extensive experience in the practice of psychedelic therapy in the research setting, working on studies of psychedelic interventions for a
variety of clinical indications. I seek to understand and develop novel and holistic treatments for mental health concerns. To that end, I’ve acted as a co-investigator, study physician, trainer, clinical supervisor, and adherence rater for many clinical trials of psychedelic treatments for various psychedelic trials. My efforts in the research setting are motivated by a desire to support the patients who are suffering, and the trainees who hope to serve them. Given my holistic orientation, I have a particular interest in the role of psychotherapy and the therapeutic relationship in the efficacy of these emerging treatments.